Skip to main content
Fig. 4 | Journal of Hematology & Oncology

Fig. 4

From: Decitabine demonstrates antileukemic activity in B cell precursor acute lymphoblastic leukemia with MLL rearrangements

Fig. 4

DEC decelerates blast frequency in BCP-ALL xenograft models. In vivo efficacy of DEC and DEC + AraC was investigated with flow cytometry of blood, BM, and spleen in SEM-ffluc and RS4;11-ffluc xenografts. a The longitudinal mean leukemic blast frequency (%GFP+) in blood after treatment is summarized for SEM-ffluc and RS4;11-ffluc. Each group comprises of nine mice. b At day 30, blast frequency (%GFP+) in BM, spleen, and blood is displayed for DEC-, DEC + AraC-, and saline-treated mice

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us